SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

doi:10.1097/HS9.0000000000000547

Editorial

. 2021 Feb 17;5(3):e547.

doi: 10.1097/HS9.0000000000000547. eCollection 2021 Mar.

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

Maria Gavriatopoulou¹, Ioannis Ntanasis-Stathopoulos¹, Eleni Korompoki¹, Evangelos Terpos¹, Meletios A Dimopoulos¹

Affiliations

PMID: 33623886
PMCID: PMC7892292
DOI: 10.1097/HS9.0000000000000547

Editorial

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

Maria Gavriatopoulou et al. Hemasphere. 2021.

. 2021 Feb 17;5(3):e547.

doi: 10.1097/HS9.0000000000000547. eCollection 2021 Mar.

Authors

Maria Gavriatopoulou¹, Ioannis Ntanasis-Stathopoulos¹, Eleni Korompoki¹, Evangelos Terpos¹, Meletios A Dimopoulos¹

Affiliation

¹ Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

PMID: 33623886
PMCID: PMC7892292
DOI: 10.1097/HS9.0000000000000547

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Cited by

Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis.
Schiller Salton N, Szwarcwort M, Tzoran I, Horowitz NA, Zuckerman T, Horesh N, Shachor-Meyouhas Y, Hussein K, Lavi N. Schiller Salton N, et al. Am J Hematol. 2021 Dec 1;96(12):E475-E478. doi: 10.1002/ajh.26373. Epub 2021 Oct 16. Am J Hematol. 2021. PMID: 34622495 Free PMC article. No abstract available.
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma.
Terao T, Yamashita T, Fukumoto A, Kamura Y, Ikeda D, Kuzume A, Tabata R, Tsushima T, Miura D, Narita K, Takeuchi M, Doi M, Umezawa Y, Otsuka Y, Takamatsu H, Matsue K. Terao T, et al. Int J Hematol. 2022 May;115(5):737-747. doi: 10.1007/s12185-022-03300-4. Epub 2022 Feb 21. Int J Hematol. 2022. PMID: 35190963 Free PMC article.
Cancer, more than a "COVID-19 co-morbidity".
Jani CT, Schooley RT, Mckay RR, Lippman SM. Jani CT, et al. Front Oncol. 2023 Mar 13;13:1107384. doi: 10.3389/fonc.2023.1107384. eCollection 2023. Front Oncol. 2023. PMID: 36994197 Free PMC article. Review.
Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients.
Nakazawa H, Sakai K, Sudo Y, Iwabuchi R, Sakai H, Nishina S, Kawakami T, Kawakami F, Matsuzawa S, Ito T, Kitahara M, Kamijo Y, Umemura T, Ushiki A, Kanai S, Tsuchiya H, Ishida F. Nakazawa H, et al. Transpl Immunol. 2022 Dec;75:101713. doi: 10.1016/j.trim.2022.101713. Epub 2022 Sep 12. Transpl Immunol. 2022. PMID: 36100196 Free PMC article.
Correlation of SARS‑CoV‑2 to cancer: Carcinogenic or anticancer? (Review).
Li YS, Ren HC, Cao JH. Li YS, et al. Int J Oncol. 2022 Apr;60(4):42. doi: 10.3892/ijo.2022.5332. Epub 2022 Mar 2. Int J Oncol. 2022. PMID: 35234272 Free PMC article.

See all "Cited by" articles

References

1. Anderson EJ, Rouphael NG, Widge AT, et al. ; mRNA-1273 Study Group. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020; 383:2427–2438 - PMC - PubMed
1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383:2603–2615 - PMC - PubMed
1. Fanciullino R, Ciccolini J, Milano G. COVID-19 vaccine race: watch your step for cancer patients. Br J Cancer. 2020 December 7. [Epub ahead of print]. doi: 10.1038/s41416-020-01219-3 - PMC - PubMed
1. Lee LYW, Cazier JB, Starkey T, et al. ; UK Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020; 21:1309–1316 - PMC - PubMed
1. Vijenthira A, Gong IY, Fox TA, et al. . Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020; 136:2881–2892 - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

[1] Anderson EJ, Rouphael NG, Widge AT, et al. ; mRNA-1273 Study Group. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020; 383:2427–2438 - PMC - PubMed

[2] Anderson EJ, Rouphael NG, Widge AT, et al. ; mRNA-1273 Study Group. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020; 383:2427–2438 - PMC - PubMed

[3] Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383:2603–2615 - PMC - PubMed

[4] Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383:2603–2615 - PMC - PubMed

[5] Fanciullino R, Ciccolini J, Milano G. COVID-19 vaccine race: watch your step for cancer patients. Br J Cancer. 2020 December 7. [Epub ahead of print]. doi: 10.1038/s41416-020-01219-3 - PMC - PubMed

[6] Fanciullino R, Ciccolini J, Milano G. COVID-19 vaccine race: watch your step for cancer patients. Br J Cancer. 2020 December 7. [Epub ahead of print]. doi: 10.1038/s41416-020-01219-3 - PMC - PubMed

[7] Lee LYW, Cazier JB, Starkey T, et al. ; UK Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020; 21:1309–1316 - PMC - PubMed

[8] Lee LYW, Cazier JB, Starkey T, et al. ; UK Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020; 21:1309–1316 - PMC - PubMed

[9] Vijenthira A, Gong IY, Fox TA, et al. . Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020; 136:2881–2892 - PMC - PubMed

[10] Vijenthira A, Gong IY, Fox TA, et al. . Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020; 136:2881–2892 - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

Affiliation

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

Authors

Affiliation

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous